We also identified concomitant BRAF/TP53 mutations in the only mucinous ovarian cancer sample, particularly the activating mutation p.V600E in BRAF and missense change p.C176F in TP53. Mucinous ovarian carcinomas are frequently mutated in KRAS and to a lesser extent TP53, and recent studies using NGS technology revealed activating mutations in BRAF (5–23%) [32,66], demonstrating frequent RAS-RAF-MEK-ERK pathway activation. The gene discussed is KRAS; the disease is ovarian mucinous adenocarcinoma.